Patent ID: 8409613

Claim:
A method for the prophylactic treatment of migraine headaches comprising administering a gastric retained dosage form comprising a therapeutically effective amount of gabapentin or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment, wherein the dosage form comprises a matrix and the gabapentin is dispersed in the matrix, and wherein upon ingestion of the dosage form the gabapentin is released from the matrix into the upper gastrointestinal tract over about 5-12 hours at a rate sufficient to achieve a lower maximum plasma concentration (C max ) than that provided by an immediate release dosage form comprising an equal amount of gabapentin, and bioavailability of the gabapentin is at least 80% of that provided by the immediate release dosage form comprising an equal amount of gabapentin as measured by the area under the plasma concentration-time curve, AUC inf .